NCT Number: NCT00129571
Study of XL820 in Adults With Solid Tumors
The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.
Looking for future studies?
Notify MeKey information
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Advanced solid tumor
- Cancer for which standard therapies do not exist or are no longer effective
- Life expectancy of > 3 months
- Adequate bone marrow, liver, and kidney function
- Willing to use accepted method of contraception during the course of the study
- Negative pregnancy test (females)
- Written informed consent
Exclusion criteria
- Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
- Investigational drug within 30 days of the start of treatment
- Subjects with known brain metastasis
- Uncontrolled medical disorder such as infection or cardiovascular disease
- Subjects known to be HIV positive
- Pregnant or breastfeeding women
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Exelixis
Industry
Registry information
Official study title
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors
Important dates
- Study start
- 2005
- First posted
- Aug 12, 2005
- Registry last updated
- Jun 4, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
SMLI With Hispanic Cancer Survivors and Caregivers
NCT05364372
Behavior, Cancer
Tucson, Arizona, United States
View Trial DetailsNeuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
NCT01445483
Brain Diseases, Brain Metastasis
Bethesda, Maryland, United States
View Trial DetailsDiabetes Prevention Program Outcomes Study
NCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsTemozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
NCT03556384
Brain Diseases, Cancer
La Jolla, California, United States
View Trial Details